Lannett Company, Inc. (LCI) Analysts See $0.65 EPS

August 12, 2018 - By Jenna Rose

Investors sentiment decreased to 1.18 in Q1 2018. Its down 0.20, from 1.38 in 2017Q4. It fall, as 29 investors sold Lannett Company, Inc. shares while 36 reduced holdings. 24 funds opened positions while 53 raised stakes. 36.15 million shares or 1.94% less from 36.87 million shares in 2017Q4 were reported.
Brandywine Global Mngmt Limited Liability Corporation holds 41,098 shares or 0% of its portfolio. Hays Advisory Ltd Liability has invested 0% in Lannett Company, Inc. (NYSE:LCI). Globeflex Cap Lp reported 31,940 shares. Thrivent For Lutherans, Minnesota-based fund reported 19,459 shares. California State Teachers Retirement System holds 43,184 shares or 0% of its portfolio. Dupont Mgmt invested in 0.02% or 56,934 shares. Goldman Sachs Grp reported 188,895 shares or 0% of all its holdings. Element Capital Management Ltd Company has 13,936 shares for 0.01% of their portfolio. Rhumbline Advisers holds 0% in Lannett Company, Inc. (NYSE:LCI) or 75,111 shares. Swiss Commercial Bank invested in 48,800 shares. Moreover, State Of Tennessee Treasury Department has 0% invested in Lannett Company, Inc. (NYSE:LCI). State Common Retirement Fund reported 0% stake. Sector Pension Investment Board invested in 0% or 18,566 shares. Public Employees Retirement Sys Of Ohio, Ohio-based fund reported 22,340 shares. New York State Teachers Retirement Sys has 0% invested in Lannett Company, Inc. (NYSE:LCI) for 50,293 shares.

Since May 10, 2018, it had 2 insider buys, and 0 sales for $407,710 activity. Crew Timothy C also bought $29,460 worth of Lannett Company, Inc. (NYSE:LCI) shares.

Analysts expect Lannett Company, Inc. (NYSE:LCI) to report $0.65 EPS on August, 22.They anticipate $0.25 EPS change or 62.50 % from last quarter’s $0.4 EPS. LCI’s profit would be $24.71M giving it 5.21 P/E if the $0.65 EPS is correct. After having $0.80 EPS previously, Lannett Company, Inc.’s analysts see -18.75 % EPS growth. The stock decreased 0.73% or $0.1 during the last trading session, reaching $13.55. About 443,357 shares traded. Lannett Company, Inc. (NYSE:LCI) has declined 16.75% since August 13, 2017 and is downtrending. It has underperformed by 29.32% the S&P500.

Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company has market cap of $515.09 million. The firm offers solid oral, extended release, topical, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, patch, foam, buccal, sublingual, soft gel, and injectable dosages. It has a 11.25 P/E ratio. It also provides its products for various medical indications comprising glaucoma, cholesterol, muscle spasm, migraine, pain management, cardiovascular, antipsychosis, gastrointestinal, urinary, bronchospasms, respiratory, gallstone, congestive heart failure, thyroid deficiency, central nervous system, and gout.

More news for Lannett Company, Inc. (NYSE:LCI) were recently published by: Streetinsider.com, which released: “Lannett (LCI) Enters Licensing Agreement For Generic Concerta” on August 03, 2018. Globenewswire.com‘s article titled: “Detailed Research: Economic Perspectives on A10 Networks, Lannett, Navigant Consulting, EastGroup Properties …” and published on August 06, 2018 is yet another important article.

Lannett Company, Inc. (NYSE:LCI) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.